Evidence map›Paper›PMID 30249388›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2018

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Julia A Sung, Shabnum Patel, Matthew L Clohosey, Lauren Roesch, Tamara Tripic, JoAnn D Kuruc, Nancie Archin, Patrick J Hanley, C Russell Cruz, Nilu Goonetilleke and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02208167 (IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02208167 phase1completednot on this map

IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chronic Infection

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2015 to 2017Enrolled6ConditionsHIVArmsHXTC infusion
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. EfficientFrontiers in immunology · 2023
    Article
  14. Article
  15. The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Julia A SungUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Shabnum PatelCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA.
Matthew L ClohoseyUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Lauren RoeschCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA.
Tamara TripicSection of Hematology-Oncology, Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
JoAnn D KurucUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nancie ArchinUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Patrick J HanleyCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA.
C Russell CruzCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA.
Nilu GoonetillekeUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Joseph J EronUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Clio M RooneySection of Hematology-Oncology, Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
Cynthia L GayUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Catherine M BollardCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC 20010, USA. Electronic address: cbollard@childrensnational.org.
David M MargolisUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: dmargo@med.unc.edu.
University of North Carolina at Chapel Hill · USChildren's National · USBaylor College of Medicine · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
North Carolina Translational & Clinical Sciences Institute (NC TraCS)KL2TR001109 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$5.7M
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV InfectionR01HL132791 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOLLARD, CATHERINE M., MARGOLIS, DAVID M. · 2016 to 2020
$3.8M
NCATS NIH HHS KL2 TR001109NCI NIH HHS P30 CA016086NHLBI NIH HHS N01 HB037163NHLBI NIH HHS N01HB37163NHLBI NIH HHS R01 HL132791NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI126619
6 · The paper itself

Abstract

Adoptive T cell therapy has had dramatic successes in the treatment of virus-related malignancies and infections following hematopoietic stem cell transplantation. We adapted this method to produce ex vivo expanded HIV-specific T cells (HXTCs), with the long-term goal of using HXTCs as part of strategies to clear persistent HIV infection. In this phase 1 proof-of-concept study (NCT02208167), we administered HXTCs to antiretroviral therapy (ART)-suppressed, HIV-infected participants. Participants received two infusions of 2 × 10

Indexed as

Cell- and Tissue-Based TherapyAdultAgedAntiretroviral Therapy, Highly ActiveCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleGenetic TherapyHIV-1HIV InfectionsHumansMaleMiddle AgedT-LymphocytesVirus ActivationVirus Replicationcell therapyHIVlatency

Identifiers

PMID30249388
PMCPMC6171327
OpenAlexW2891864941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.